Other equities research analysts have also issued research reports about the stock. Wolfe Research upgraded shares of Roche Holdings AG Basel from a market perform rating to an outperform rating in a research note on Wednesday, May 13th. HSBC upgraded shares of Roche Holdings AG Basel from a reduce rating to a hold rating in a research report on Thursday, April 30th. Zacks Investment Research upgraded shares of Roche Holdings AG Basel from a hold rating to a buy rating and set a $48.00 target price for the company in a research report on Friday, April 24th. Goldman Sachs Group upgraded shares of Roche Holdings AG Basel from a buy rating to a conviction-buy rating in a research report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. restated an overweight rating on shares of Roche Holdings AG Basel in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Roche Holdings AG Basel presently has an average rating of Buy and a consensus price target of $48.00.
RHHBY opened at $44.72 on Tuesday. The firm has a market cap of $306.26 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 2.99 and a beta of 0.40. Roche Holdings AG Basel has a fifty-two week low of $33.14 and a fifty-two week high of $46.00. The company’s 50-day moving average price is $44.09 and its 200 day moving average price is $41.84. The company has a quick ratio of 1.04, a current ratio of 1.30 and a debt-to-equity ratio of 0.35.
Several institutional investors have recently bought and sold shares of RHHBY. Arkadios Wealth Advisors bought a new position in shares of Roche Holdings AG Basel in the first quarter valued at approximately $37,000. Bartlett & Co. LLC bought a new position in shares of Roche Holdings AG Basel in the first quarter valued at approximately $48,000. Chevy Chase Trust Holdings Inc. bought a new position in shares of Roche Holdings AG Basel in the fourth quarter valued at approximately $50,000. Eudaimonia Partners LLC boosted its holdings in shares of Roche Holdings AG Basel by 88.1% in the first quarter. Eudaimonia Partners LLC now owns 3,337 shares of the company’s stock valued at $135,000 after acquiring an additional 1,563 shares in the last quarter. Finally, Angeles Investment Advisors LLC bought a new position in shares of Roche Holdings AG Basel in the first quarter valued at approximately $214,000. Institutional investors and hedge funds own 0.30% of the company’s stock.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Further Reading: Market Timing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Roche Holdings AG Basel Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Roche Holdings AG Basel and related companies with MarketBeat.com’s FREE daily email newsletter.